Breaking News

Canon Medical Offers New Liver Reporting Tool for Ultrasound

To help easily and accurately determine cut off values, Canon Medical Systems USA, Inc.’s premium AplioTM i-series ultrasound platform is now available with software to display the calculated measurement averages from multiple samples of the liver, customizable based on the “Rule of Four.”

Rithem Life Sciences Joins Innovators’ Network at American Heart Association Center for Health Technology & Innovation

The Center is focused on building and fostering health technology relationships to develop innovative and scalable solutions.

1st Patients Enrolled in STEM Trial for `Treatment of Chronic Subdural Hematoma

This marks the first patients enrolled in a prospective, randomized, international trial of a liquid embolic agent for the treatment of chronic subdural hematoma (cSDH), a common disease affecting primarily older adults.

Genius AI Detection Receives FDA Clearance – New Deep Learning-based Software Designed to Help Radiologists Detect Subtle Potential Cancers in Breast Tomosynthesis Images

This new technology, represents a pivotal milestone in the early detection of breast cancer, as studies showed Genius AI Detection software aids in the identification and early detection of breast cancer when used with the Genius® 3D Mammography™ exam.

Passio Pump Drainage System Granted 510(k) for Additional Indication for Home Use

The Passio Pump Drainage System consists of the Passio Catheter, a Handheld Control Unit (pump) and a Disposable Collection Kit, which includes a redressing kit, for drainage of recurrent and symptomatic pleural effusion.

Dr. Stephen K. Klasko Is Appointed to the Nuvo Group BOD

September 1, 2020

Dr. Stephen K. Klasko has been appointed to the Board of Directors of Nuvo Group. The news was announced today. He is President of Thomas Jefferson University and Chief Executive Officer of Jefferson Health.

Dr. Stephen K. Klasko brings a rare combination of experience as a former practicing OB/GYN, a pioneer in envisioning ‘a hospital with no address,’ and the CEO of a major health system at the vanguard of telehealth.

Nuvo is building the foundation of a disruption in pregnancy care delivery—a specialty that has seen little innovation in decades and is being left behind in the movement toward ‘a hospital with no address. Steve’s unparalleled vision, clinical, and operational experience makes him uniquely suited to provide insights, strategic guidance, and market connections that will help Nuvo revolutionize pregnancy care for the 21st century and create extraordinary value for all system stakeholders,” said Oren Oz, Founder and CEO of Nuvo Group.

Nuvo Group shares my vision of what the next generation of healthcare must be—namely ‘healthcare at any address,’ said Dr. Klasko. “In the United States, an emphasis on ‘sick care’ has led to pregnancy being viewed as a disease, defined by a hospital-centric model that has frustrated women at many levels and increased maternal neonatal disparities. Otherwise healthy pregnant women don’t view themselves as patients—and do not want to go where the sickest people are for testing. I look forward to contributing to the success of the INVU platform in creating a mom-centric experience that connects pregnant women and providers and forges a path toward pregnancy population health.”

Dr. Klasko is a transformative leader and advocate for a revolution who, as President and CEO of Jefferson Health since 2013, has led one of the nation’s fastest-growing academic health institutions based on his vision of re-imagining healthcare and higher education. Prior to Jefferson Health, he served as dean of two medical colleges and the leader of three academic health centers.

Dr. Klasko’s own research has focused on physician leadership. After receiving his MBA from the Wharton School of Business of the University of Pennsylvania, he developed research about selecting and educating physicians to be leaders of change. He launched a unique medical education program at the University of South Florida, called SELECT (Scholarly Excellence, Leadership Education, Collaborative Training), to choose and mentor medical students based on emotional intelligence and leadership potential.

Latest Posts

Face Shield Market Is Estimated to Grow Globally from USD 3.0 billion in 2020 to USD 4.1 Bil by 2025, at a CAGR of 65%

Face shield market size is estimated to grow globally from USD 3.0 billion in 2020 to USD 4.1 billion by 2025, at a CAGR of 6.5%.

Acquisition of Moldworx, LLC by Sunningdale Tech Ltd Completed Effective November 6, 2020

On November 6, 2020, the acquisition of Moldworx by global precision plastics manufacturer, Sunningdale Tech Ltd (Singapore) via its wholly-owned subsidiary, Sunningdale Tech Inc, a Michigan Corporation, was completed.

1st PSMA-Targeted PET Imaging Drug for Men with Prostate Cancer Receives FDA Approval

"Ga 68 PSMA-11 is an important tool that can aid health care providers in assessing prostate cancer," said Alex Gorovets, M.D., acting deputy director of the Office of Specialty Medicine in FDA's Center for Drug Evaluation and Research. "With this first approval of a PSMA-targeted PET imaging drug for men with prostate cancer, providers now have a new imaging approach to detect whether or not the cancer has spread to other parts of the body."

Don't Miss

New England Biolabs Announces Further Expansion of Their RNA Depletion Product Portfolio with the Launch of the NEBNext Custom RNA Depletion Design Tool and NEBNext RNA Depletion Core Reagent...

Together, these enable a fully customizable workflow for improved removal of specific RNAs, including abundant RNAs such as ribosomal RNA

INTERCEPT Blood System for Cryoprecipitation Receives FDA Approval States Cerus Corporation

The system is used to produce Pathogen Reduced Cryoprecipitated Fibrinogen Complex for the treatment and control of bleeding, including massive hemorrhage, associated with fibrinogen deficiency. 

Genetron Health Provides Update on HCCscreen™ for Liver Cancer Early Screening in China

Establishes joint venture with Wuxi municipal government; Expects the commercialization and revenues of HCCscreen to accelerate in China.

Research Paper Showing ProtoKinetix AAGP® Enhanced Stem Cell Derived Retina Precursor Cells Restoration of Vision

ProtoKinetix notes the research paper has been submitted to a prestigious journal specializing in tissue regeneration for peer review and editing.

OrganaBio to Expand Its cGMP Cell and Gene Therapy Manufacturing Facility: 19,000 Sq. Ft. Slated to Commence Operations In Q3 2021

OrganBio, a Miami-based cGMP facility, will include process development space, ISO 7 cleanrooms, state-of-the-art scientific equipment, analytics and QC laboratories, and a suite of support services to enable OrganaBio and its partners to rapidly and economically self-manufacture clinical materials.